In summary, these findings are in line with our previous data from germ-line knockout studies and indicate that the Nr2f6CRISPR/Cas9 knockout T cells are comparable to germline Nr2f6-deficient T cells, a result providing an independent confirmation of the cancer immune checkpoint function of lymphatic NR2F6. The gene discussed is NR2F6; the disease is cancer.